| Literature DB >> 30616017 |
Kun-Ming Tian1, Jing-Jie Li2, Suo-Wen Xu3.
Abstract
Rutaecarpine is a bioactive alkaloid isolated from Evodia rutaecarpa (Wu Zhu Yu, Family: Rutaceae), a versatile medicinal herb which is clinically used to treat headache, abdominal pain, postpartum hemorrhage, dysentery, and amenorrhea in China. As one of the most representative indolopyridoquinazoline alkaloids of Evodia rutaecarpa, rutaecarpine has broad pharmacological actions in treating various cardiovascular, cerebrovascular, and metabolic diseases. The cardiovascular actions of rutaecarpine have aroused intense research interest due to its purported inotropic and chronotropic, vasodilatory, anti-platelet activation, anti-oxidant, anti-inflammatory, and lipid-lowering effects. Biochemical and pharmacological studies have illustrated the molecular targets of rutaecarpine, such as TRPV1, CGRP, AMPK, ABCA1, and β1-AR. Furthermore, several rutaecarpine derivatives (such as bromorutaecarpine and fluororutaecarpine) have been shown to possess cardioprotective and vasculoprotective effects with improved safety profile. Hereby, we provide a systematic overview of pharmacological actions, toxicological effects, and molecular targets of rutaecarpine in cardiovascular disease prevention/treatment, aiming to exploit the therapeutic potential of rutaecarpine and its derivatives in treating cardiovascular diseases.Entities:
Keywords: CGRP; Cardiovascular diseases; Dehydroevodiamine (PubChem CID: 9817839); Evodia rutaecarpa; Evodiamine (PubChem CID: 442088); Rutaecarpine; Rutaecarpine (PubChem CID: 65752); TRPV1; Therapeutics; Wu Zhu Yu
Mesh:
Substances:
Year: 2019 PMID: 30616017 DOI: 10.1016/j.phrs.2018.12.019
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658